Keller adds his colours to Spectrum as COO
This article was originally published in Scrip
Spectrum Pharmaceuticals has appointed Ken Keller its chief operating officer. Prior to joining Spectrum, Mr Keller spent 21 years at Amgen. His most recent role was vice-president and general manager, bone health business unit.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.